Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized dose-finding study of LFB-R593 vs Rhophylac in healthy RhD-negative volunteers
2009-011017-24Phase 2Completed
- Sponsor
- LFB Group
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of roledumab in Rh isoimmunization and Hemolytic disease of the fetus and newborn due to RhD isoimmunization (2 arms), sponsored by LFB Group. Started Apr 2009; status: completed.
02
Drugs
roledumab
03
Conditions
Rh isoimmunizationHemolytic disease of the fetus and newborn due to RhD isoimmunization
Beyond the preview
Go deeper on 2009-011017-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011017-24.